MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, announced that Dr. Samuel Barone, MD, Senior Vice President, Clinical Development will provide a brief corporate overview and data presentation today at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting in Chicago, IL.
The presentation is now available on the Company’s website at www.adverumbio.com.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline that includes product candidates to treat wet AMD, A1AT deficiency, and hereditary angioedema, among other diseases. We are leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information please visit www.adverumbio.com
Contact for Adverum:
Tricia Truehart
Vice President
The Trout Group LLC
646-378-2953
ttruehart@troutgroup.com
Adverum Biotechnologies, Inc.